Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepu Madduri

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forwardBo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Journal of Hematology & Oncology|July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forwardBo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 StudyMyo Htut, Binod Dhakal, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple MyelomaDeepak Perumal, Naoko Imai, Alessandro Laganà, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
JCO Precision Oncology|February 2, 2019
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics ApproachAlessandro Laganà, Itai Beno, David Melnekoff, et al.
Nature Medicine|December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapyOliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Cancer|March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myelomaThomas G Martin, Nina Shah, Joshua Richter, et al.
The New England Journal of Medicine|May 3, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, Jesus Berdeja, Yi Lin, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forwardBo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Journal of Hematology & Oncology|July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forwardBo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 StudyMyo Htut, Binod Dhakal, Adam D Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple MyelomaDeepak Perumal, Naoko Imai, Alessandro Laganà, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
JCO Precision Oncology|February 2, 2019
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics ApproachAlessandro Laganà, Itai Beno, David Melnekoff, et al.
Nature Medicine|December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapyOliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
JCO Precision Oncology|June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple MyelomaPaula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Cancer|March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myelomaThomas G Martin, Nina Shah, Joshua Richter, et al.
The New England Journal of Medicine|May 3, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, Jesus Berdeja, Yi Lin, et al.
Pageof 5